as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL). Ezharmia (valemetostat tosylate) remains the first and only drug in the class to be approved for marketing around the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback